2016 American Transplant Congress
Acute Rejection: A Major Cause of Death-Censored Kidney Allograft Failure.
1Weill Medical College of Cornell University, New York; 2The Rogosin Institute, New York.
Introduction:The role of acute rejection as a cause of kidney allograft failure is not well defined in the current era of immunosuppression. We analyzed the…2016 American Transplant Congress
Treatment for AMR and DSA: A Center Based Review of Pediatric Orthotopic Heart Transplant Recipients.
PURPOSE: The aim of this study was to retrospectively analyze the clinical course of pediatric orthotopic heart transplant patients diagnosed with antibody mediated rejection (AMR+)…2016 American Transplant Congress
Membranoproliferative Glomerulonephritis Pattern without Immunoglobulin and Complement Deposition in Renal Allograft Was Related to the Injury of Antibody-Mediated Rejection.
National Clinical Research Center of Kidney Diseases, Nanjing, China.
Background: Differential diagnosis of Membranoproliferative Glomerulonephritis (MPGN) in renal allograft was difficult because of the confused etiology. Recurrent or de novo MPGN were related to…2016 American Transplant Congress
Plasma Cell Frequency in Renal Rejection After Treatment with Alemtuzumab.
Transplantation, The University of Toledo, Toledo, OH.
Background: The highly successful induction drug Alemtuzumab (Campath) is commonly used prior to renal transplant. Yet, it does not completely ablate plasma cell which, in…2016 American Transplant Congress
Type of Sensitization Does Not Impact Kidney Graft Outcome in Weakly Sensitized Patients.
Introduction: The impact of low level sensitization on kidney transplant (KTx) outcomes is unclear. While limited data suggest that KTx outcomes are comparable between weakly…2016 American Transplant Congress
Post-Trial Experience with Belatacept: A Large Single Center Experience.
Emory Transplant Center, Atlanta, GA.
Evaluation of belatacept in clinical trials revealed significant improvements in renal function and cardiovascular risk leading to superior survival. Despite these proven benefits higher rates…2016 American Transplant Congress
Real Time Assessment of Kidney Transplant Indication Biopsies by Microarrays: First Results of the INTERCOMEX Study.
1University of Alberta, Edmonton, Canada; 2ATAGC, Edmonton, Canada.
Oncology uses central molecular tissue assessment (MTA) to guide management but the potential of this approach in transplantation is not known. We undertook a prospective…2016 American Transplant Congress
Ageing as a Barrier to Transplant Tolerance.
Surgery/Transplant, Massachusetts General Hospital, Harvard Medical, Boston, MA.
We recently demonstrated that ageing also impedes development of transplantation tolerance. Unlike their young counterparts (8-12 weeks of age) aged male recipients (greater than 12…2016 American Transplant Congress
Proteoforms: Novel Biomarkers for Acute Rejection in Liver Transplant Recipients.
1Northwestern, Chicago; 2UPMC, Pittsburgh.
Background: Biomarker profiles diagnostic of acute rejection (AR) in liver transplant (LT) recipients could enhance the diagnosis and management of recipients. Our aim was to…2016 American Transplant Congress
Effect of Complement Inhibition Therapy (Eculizumab) in Patients with C1q-Binding Donor-Specific Anti-HLA Antibodies: A Molecular Appraisal.
Complement-binding anti-HLA DSA have demonstrated higher rejection rate and decreased allograft outcome. We investigated the effect of terminal complement inhibition (Eculizumab) in a cohort of…
- « Previous Page
- 1
- …
- 131
- 132
- 133
- 134
- 135
- …
- 172
- Next Page »